Gilotrif (afatinib)

Our study demonstrated that both afatinib and osimertinib as first-line treatments offer favorable median OS in patients with advanced EGFR-mutant NSCLC. In addition, we recommend that patients receiving afatinib as first-line therapy undergo sequential osimertinib treatment, regardless of their T790M mutation status.

Consistently, afatinib treatment resulted in marked tumor shrinkage and suppression of EGFR signaling in the established mDEL OsiR #1/#3 in vivo. These findings establish secondary Egfr V804F/EGFR V802F as an on-target osimertinib resistance mechanism, providing a preclinical rationale for evaluating afatinib in biomarker-selected patients harboring this alteration.

Likewise, a combination of selective inhibitors of KRAS (RMC-6236/daraxonrasib), EGFR family (afatinib), and STAT3 (SD36) induced the complete regression of orthotopic PDAC tumors with no evidence of tumor resistance for over 200 d posttreatment. Of importance, this combination therapy was well tolerated. In sum, these results should guide the development of new clinical trials that may benefit PDAC patients.

Among 56 patients who received subsequent systemic therapy, clinical outcomes were comparable between ICI plus platinum doublet and platinum doublet alone. These findings indicate that afatinib and osimertinib provide comparable survival outcomes as first-line therapies for NSCLC with UMs, with treatment effects varying by molecular subtype, while subsequent ICI-based regimens may confer limited additional benefit.

Molecular docking simulations suggested promising drug repurposing avenues, particularly with afatinib and crizotinib, for GABRD inhibition. GABRD gene may serve as a novel biomarker in the diagnosis, prognosis and immune infiltrates of CRC patients.

Additionally, the model accurately predicted patient sensitivity to specific chemotherapeutic agents like afatinib and dasatanib...We developed a signature of lncRNAs linked to crotonylation that offers dependable prognostic insights and characterizes the immune microenvironment within GC. However, additional investigation is necessary to confirm its practical applications in clinical settings.

Successful generation of a BrM-derived organoid line enabled high-throughput drug screening, which recapitulated the patient's clinical resistance to standard therapies [gemcitabine/nab-paclitaxel, 5-fluorouracil (5-FU)], and showed sensitivity to afatinib, everolimus and RMC-6236...Physicians should also be aware that KRAS wild-type pancreatic cancer with atypical amplifications is likely to exhibit unique metastatic tropisms. Finally, we suggest that patient-derived organoids pharmacotyping can mirror clinical drug responses and help evaluate therapeutic avenues for patient treatment.

As second-line therapy, he was treated with pembrolizumab plus carboplatin and pemetrexed for four cycles, followed by 13 cycles of maintenance pembrolizumab and pemetrexed, and subsequently five cycles of pembrolizumab monotherapy, maintaining stable disease until further progression. He was then started on low-dose afatinib (20 mg once daily) as third-line therapy, achieving a partial response that has been maintained for 18 months without severe adverse events. This case suggests that low-dose afatinib may provide durable disease control with acceptable tolerability after progression on osimertinib in advanced EGFR L861Q-mutated NSCLC.

Combination index analysis demonstrated that co-treatment with the EGFR inhibitor afatinib and lorlatinib synergistically inhibited the growth of lorlatinib-resistant PUMC-NB1-R and SH-SY5Y-R cells (combination index＜1). High expression and activation of EGFR, leading to bypass activation of the ALK downstream pathway, is a key molecular mechanism of lorlatinib resistance in neuroblastoma. This suggests that combination therapy could be used clinically to prevent and treat resistance.

P2/3, N=174, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026

According to available data, rare G719X/S768I variants (2.0%) may benefit from Afatinib, but Exon 19 deletions were the most common subtype in clinical settings (70.4% of EGFR-positive cases), indicating the use of first-line Osimertinib. However, the study's retrospective design and small sample sizes for uncommon mutation subtypes are among its limitations, which call for additional prospective validation in larger cohorts. These findings highlight the need for specialised diagnostic and treatment approaches in underrepresented populations and advance our understanding of the heterogeneity of EGFR mutations across ethnic groups.

This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor-mutated non-small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.